Copyright
©The Author(s) 2016.
World J Stem Cells. Jul 26, 2016; 8(7): 223-230
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Figure 1 Number of patients assessed for glycated hemoglobin: Before and after the human embryonic stem cell treatment.
NFS grades - Grade 1: > 9.0%; Grade 2: 7.0%-9.0%; Grade 3: 6.5%-7.0%; Grade 4: 6.0%-6.5%; Grade 5 (HPG): < 6.0%. HbA1c: Glycated hemoglobin; NFS: Nutech functional score; HPG: Highest possible grade.
Figure 2 Number of patients assessed for insulin: Before and after the human embryonic stem cell treatment.
NFS grades - Grade 1: > 100 IU; Grade 2: 80-100 IU; Grade 3: 60-80 IU; Grade 4: 20-60 IU; Grade 5 (HPG): 0-20 IU. NFS: Nutech functional score; HPG: Highest possible grade.
Figure 3 Number of patients assessed for number of medications used without insulin: Before and after the human embryonic stem cell treatment.
NFS grades - Grade 1: > 5; Grade 2: < 4; Grade 3: < 3; Grade 4: > 2; Grade 5 (HPG): No medications taken. NFS: Nutech functional score; HPG: Highest possible grade.
Figure 4 Number of patients assessed for number of medications used with insulin: Before and after the human embryonic stem cell treatment.
NFS grades - Grade 1: Insulin with > 4 medicines; Grade 2: Insulin with 4 medicines; Grade 3: Insulin with 3 medicines; Grade 4: Insulin with 2 medicines; Grade 5 (HPG): No medications required. NFS: Nutech functional score; HPG: Highest possible grade.
- Citation: Shroff G. Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus. World J Stem Cells 2016; 8(7): 223-230
- URL: https://www.wjgnet.com/1948-0210/full/v8/i7/223.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v8.i7.223